Topotecan disposition in an anephric child

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 9, 2004, Pages 596-600

  Iacono, Lisa C ^a   Adams, Denise ^b   Homans, Alan C ^c   Guillot, Ann ^c   McCune, Jeannine S ^d   Stewart, Clinton F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Cincinnati Children's Hosp Med C   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hemodialysis; Pediatric; Pharmacokinetics; Renal insufficiency; Topoisomerase I inhibitors

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; DOSE KIDNEY FUNCTION RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG TOLERABILITY; HEMODIALYSIS; HUMAN; KIDNEY AGENESIS; KIDNEY FAILURE; LIVER HEMORRHAGE; LIVER METASTASIS; LUNG METASTASIS; MALE; NEPHRECTOMY; NEPHROBLASTOMA; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; CHILD; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; KIDNEY FAILURE; KIDNEY NEOPLASMS; MALE; RENAL DIALYSIS; TOPOTECAN; WILMS TUMOR;

EID: 4544225494     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000137368.27242.ca     Document Type: Article

References (20)

1. Joppert MG, Garfield DH, Gregurich MA, et al. A phase II multicenter study of combined topotecan and gemcitabine as first-line chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003;39:215-219.
2. Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res. 2003;9:633-640.
3. Furman WL, Stewart CF, Kirstein M, et al. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a Pediatric Oncology Group study. J Clin Oncol. 2002;20:1617-1624.
4. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 1996;18:352-361.
5. Pratt CB, Stewart CF, Santana VM, et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol. 1994;12: 539-543.
6. Stewart CF, Baker SD, Heideman RL, et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J Clin Oncol. 1994;12:1946-1954.
7. Furman WL, Baker SD, Pratt CB, et al. Escalating systemic exposure to topotecan following a 120-hr continuous infusion in children with relapsed acute leukemia. J Clin Oncol. 1996;14:1504-1511.
8. Herben VMM, Schoemaker NE, Rosing H, et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumors. Cancer Chemother Pharmacol. 2002;50:59-64.
9. O'Reilly S, Armstrong DK, Grochow LB. Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecol Oncol. 1997;67:329-330.
10. O'Reilly S, Rowinsky EK, Slichenmeyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol. 1996;14:3062-3073.
11. Herrington JD, Figueroa JA, Kirstein MN, et al. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. Cancer Chemother Pharmacol. 2001;47:89-93.
12. Murry DJ, Synold TW, Pui CH, et al. Renal function and methotrexate clearance in children with newly diagnosed leukemia. Pharmacotherapy. 1995;15:144-149.
13. Iacono LC, Dome JS, Panetta JC, et al. Topotecan pharmacokinetics in children with Wilms tumor and unilateral nephrectomy. Pharmacotherapy. 2003;23:410.
14. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463-3469.
15. Bai F, Kirstein MN, Hanna SK, et al. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed phase HPLC with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;784:225-232.
16. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol. 1999;43:454-460.
17. Zamboni WC, Gajjar AJ, Heideman RL, et al. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res. 1998;4:783-789.
18. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource, 1997.
19. Gibaldi M, Perrier D. Pharmacokinetics, 2d ed. New York: Marcel Dekker, 1982.
20. Saylors RL III, Stewart CF, Zamboni WC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol. 1998; 16:945-952.